1.560CAD-4.29%Mkt Cap: 119.15M CADP/E: —Last update: 2026-06-01
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) th…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap119.15M CAD
Enterprise Value124.83M CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-4.20M CAD
Revenue/Share—
Last Price1.560 CAD
Fiscal Year EndJul 2025
MR QuarterJan 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.82
PEG—
EV/EBITDA-30.34
EV/Revenue—
P/S—
P/B8.11
EPS (TTM)-0.06
EPS (Forward)-0.11
52W Range
0.840016% of range5.400
52W High5.400 CAD
52W Low0.8400 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.70%
ROA-24.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.22M CAD
CapEx (TTM)14.00K CAD
FCF Margin—
FCF Yield-0.37%
Net Debt329.00K CAD
Net Debt/EBITDA-0.08
Balance Sheet
Debt/Equity2.34
Current Ratio0.04
Quick Ratio0.02
Book Value/Sh0.2010 CAD
Cash/Share0.0000 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateAug 16, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.76.38M
Float54.27M
Insiders28.95%
Institutions0.00%
Short Interest
Short Ratio0.2d
Short % Float0.00%
Short % Out.0.00%
Shares Short614
Short (prev mo.)2.35K
Technical
SMA 501.795 (-13.1%)
SMA 2001.996 (-21.8%)
Beta-0.31
S&P 52W Chg27.70%
Avg Vol (30d)2.38K
Avg Vol (10d)380
Technical Indicators
RSI (14)39.2
MACD-0.0767
MACD Signal-0.0726
MACD Hist.-0.0040
BB Upper2.150 CAD
BB Middle1.745 CAD
BB Lower1.340 CAD
BB Width46.44%
ATR (14)0.0795 CAD
Vol Ratio (20d)0.72x